Search Results - "Nowecki, Z"

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer by Tutt, Andrew N.J, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, Geyer, Charles E

“…Among patients who had mutations in BRCA1 or BRCA2 and were at high risk for disease progression, those who were assigned to a year of olaparib adjuvant…”
Get full text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results by Pivot, X., Bondarenko, I., Nowecki, Z., Dvorkin, M., Trishkina, E., Ahn, J.-H., Im, S.-A., Sarosiek, T., Chatterjee, S., Wojtukiewicz, M.Z., Shparyk, Y., Moiseyenko, V., Bello, M., Semiglazov, V., Lee, Y., Lim, J.

“…The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete…”
Get full text

Diagnostic yield and safety of endoscopic ultrasound-guided trucut [corrected] biopsy in patients with gastric submucosal tumors: a prospective study by Polkowski, M, Gerke, W, Jarosz, D, Nasierowska-Guttmejer, A, Rutkowski, P, Nowecki, Z I, Ruka, W, Regula, J, Butruk, E

“…Endoscopic-ultrasound-guided trucut needle biopsy (EUS-TCB) has not been adequately evaluated in patients with submucosal tumors (SMTs). This prospective,…”
Get more information

Primary angiosarcoma of the breast-series of 11 consecutive cases-a single-centre experience by Kunkiel, M, Maczkiewicz, M, Jagiełło-Gruszfeld, A, Nowecki, Z

“…Angiosarcomas of the breast are rare parenchymal malignancies of the chest wall. Surgery is the main treatment modality with chemotherapy and radiotherapy used…”
Get full text

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes by Rutkowski, P, Bylina, E, Wozniak, A, Nowecki, Z.I, Osuch, C, Matlok, M, Świtaj, T, Michej, W, Wroński, M, Głuszek, S, Kroc, J, Nasierowska-Guttmejer, A, Joensuu, H

“…Abstract Background Approval of imatinib for adjuvant treatment of gastrointestinal stromal tumours (GIST) raised discussion about accuracy of prognostic…”
Get full text

The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC by Jancewicz, I., Rusetska, N., Armatowska, A., Stachowiak, M., Pogoda, K., Niwińska, A., Olszewski, W., Nowecki, Z.I., Sarnowski, T.J., Sarnowska, E., Siedlecki, J.A.

Get full text

HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch by Dubianski, R., Sarnowska, E., Leszczynski, M., Kubala, S., Olszewski, W., Rusetska, N., Jagiello-Gruszfeld, A.I., Konopinski, R., Sarnowski, T.J., Siedlecki, J.A., Nowecki, Z.I.

Get full text

Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis by Kümmel, S., Tondini, C.A., Abraham, J., Nowecki, Z.I., Itrych, B., Hitre, E., Karaszewska, B., Juarez, A., Morales-Vásquez, F., Pérez García, J.M., Cardona-Huerta, S., Heinzmann, D., He, J., Duc, A.N., Crepelle-Fléchais, A., Martín, M.

Get full text

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study by Rugo, H.S., Oliveira, M., Howell, S.J., Dalenc, F., Cortes, J., Gomez, H.L., Hu, X., Jhaveri, K.L., Krivorotko, P., Loibl, S., Morales Murillo, S., Nowecki, Z., Okera, M., Park, Y.H., Sohn, J., Toi, M., Iwata, H., Yousef, S., Zhukova, L., Logan, J., Twomey, K., Khatun, M., D’Cruz, C.M., Turner, N.C.

“…Capivasertib is a potent, selective pan-AKT inhibitor. In CAPItello-291, the addition of capivasertib to fulvestrant resulted in a statistically significant (P…”
Get full text

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level by Nowecki, Z.I., Rutkowski, P., Kulik, J., Siedlecki, J.A., Ruka, W.

“…Summary Background  There is a need for biomarkers to identify patients at risk for disease progression after resection of melanoma regional lymph node…”
Get full text

Cetuximab and panitumumab in elderly patients with metastatic colorectal cancer by Jagiello-Gruszfeld, A.I, Kosakowska, E, Nowecki, Z

Get full text

The analysis of the outcomes and factors related to iliac–obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases by Zdzienicki, M, Rutkowski, P, Nowecki, Z.I, van Akkooi, A.C.J, Michej, W, Dziewirski, W, Świtaj, T, Pieńkowski, A, Sałamacha, M, Bylina, E, Eggermont, A.M.M

“…Abstract Background We assessed clinical–pathological features and outcomes of cutaneous melanoma patients after ilio-inguinal lymph node dissection (LND) in…”
Get full text

Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection by Rutkowski, P, Dębiec-Rychter, M, Nowecki, ZI, Michej, W, Symonides, M, Ptaszynski, K, Ruka, W

“…Background  Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma of the skin characterized by the presence of specific COL1A1–PDGFB fusion…”
Get full text

In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection by Rutkowski, P., Nowecki, Z.I., Zurawski, Z., Dziewirski, W., Nasierowska-Guttmejer, A., Świtaj, T., Ruka, W.

“…This study has analyzed the incidence of in transit/local recurrences (IT/LR) in melanoma patients after sentinel node (SLN) biopsy; completion lymph node…”
Get full text

Retrospective study comparing tolerability of trastuzumab as adjuvant setting in two groups of early breast cancer patients: ≥ 70 years vs < 70 years by Jagiello-Gruszfeld, A.I, giermek, J, Dubianski, R, Maczkiewicz, M, Nowecki, Z

Get full text

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib by Ruka, W, Rutkowski, P, Szawłowski, A, Nowecki, Z, Dębiec-Rychter, M, Grzesiakowska, U, Dziewirski, W, Siedlecki, J.A, Michej, W

“…Abstract Aim Sunitinib malate therapy in inoperable and/or metastatic gastrointestinal stromal tumor (GIST) resistant to imatinib mesylate may facilitate…”
Get full text

Lymph node status and survival in cutaneous malignant melanoma—sentinel lymph node biopsy impact by Rutkowski, P, Nowecki, Z.I, Nasierowska-Guttmejer, A, Ruka, W

“…Aim: The survival benefit of sentinel lymph node biopsy (SLB) with lymphadenectomy for microscopic melanoma metastases to regional lymph nodes (SLND) is…”
Get full text

Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay by Kulik, J, Nowecki, Z I, Rutkowski, P, Ruka, W, Rochowska, M, Skurzak, H, Siedlecki, J A

“…The aim of this study was to develop a highly sensitive two-marker assay for the detection of circulating melanoma cells in patients' blood using a reverse…”
Get full text

Detection of melanoma cells in the lymphatic drainage collected after lymph node dissection (LND) in stage III melanoma patients using two-marker reverse transcriptase-polymerase chain reaction (RT-PCR) assay by Ruka, W., Rutkowski, P., Kulik, J., Nowecki, Z. I., Siedlecki, J.

Get full text

74P Clinical value of HER3/ErbB3 serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy by Kotowicz, B., Winter, P., Fuksiewicz, M., Jagiello-Gruszfeld, A.I., Nowecki, Z., Kowalska, M.M.

Get full text